Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16338382 | 0.83 | TP53 (0.33) | MEN1KMT2A | |
| SCHEMBL19873057 | 0.83 | TP53 (0.33) | MEN1KMT2A | |
| SCHEMBL19882793 | 0.81 | DPP4 (0.48) | — | |
| SCHEMBL19736334 | 0.80 | MLYCD (0.36) | MLYCDMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL16373133 | 0.80 | MLYCD (0.36) | MLYCDMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL25575538 | 0.80 | MLYCD (0.36) | MLYCDMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL29342171 | 0.78 | MLYCD (0.35) | MLYCDMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL29342194 | 0.78 | MLYCD (0.35) | MLYCDMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL12084428 | 0.77 | DPP4 (0.36) | MEN1KMT2ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL29342180 | 0.76 | MLYCD (0.34) | MLYCDMEN1KMT2ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3491922-A1 | PESTICIDAL COMPOSITIONS AND PROCESSES RELATED THERETO | Dow AgroSciences LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3013805-B1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES AND THEIR USE AS MNK1 AND/OR MNK2 KINASE INHIBITORS | EVOTEC INT GMBH (DE) | 2018-02-21 | — | — | EP | disclosed |
| US-9708274-B2 | Sulfoximine substituted quinazolines for pharmaceutical compositions | EVOTEC INTERNATIONAL GMBH (DE) | 2017-07-18 | — | — | US | disclosed |
| US-9139577-B2 | Sulfoximine substituted quinazolines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-20150005278-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005278-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | NEK5, SIK2, PDXK | MLYCD 1716/4885MEN1 774/4885KMT2A 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.